private:oncorebiopharma
|
5224789
|
Feb 17th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 16th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 15th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 14th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 13th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 12th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 11th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 10th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 9th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|
private:oncorebiopharma
|
5224789
|
Feb 8th, 2018 12:00AM
|
OnCore BioPharma Inc.
|
272
|
5.00
|
Open
|
Biotechnology
|
Feb 8th, 2017 11:57AM
|
Feb 8th, 2017 11:57AM
|
OnCore BioPharma Inc. merged with Tekmira Pharmaceuticals Corp. on March 4, 2015. Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV.
For more information please refer to www.arbutusbio.com
|
|
|
|
|
|
|
|
|
|
OnCore Biopharma
|
|
Health Care Equipment & Services
|